ArticleCPT: pharmacometrics & systems pharmacology2023

Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients.

Elena M Tosca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.